ANAB 144 SEC Filing Analysis

Latest settled — T+5d

ANAB ▼ -9.38% at T+5d

SHORT call ✓ call won +9.38% · α vs SPY +9.70% · entry $57.02 → $51.67

Next anchor: T+20d in 12d

Currently $56.07 · +1.67% from $57.02 entry (call sign-flipped)

Entry anchored
May 27, 2026
via day open

T+1d

-2.37%

call +2.37% · α +2.61%

$55.67

settled 16d ago

T+5d

-9.38%

call +9.38% · α +9.70%

$51.67

settled 10d ago

T+20d

—

call — · α —

—

in 12d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

CEO Dennis Mulroy filed a Form 144 notice to sell 10,000 shares of AnaptysBio common stock, valued at approximately $585,006 based on the filing date price. This follows a series of recent sales by Mulroy totaling over 55,000 shares in the past two weeks, representing a significant insider selling pattern ahead of potential catalysts.

Actionable Insight

The CEO's sustained selling pattern (55K+ shares in 12 days) is a bearish signal, especially given the company's $1.7B market cap and 89% analyst buy rating. Monitor for any negative news or guidance changes in the next 10-Q. The 144 is an intent to sell, but the pattern suggests the insider is actively reducing exposure.

Key Facts

CEO Dennis Mulroy filed Form 144 on 2026-05-27 to sell 10,000 shares at ~$585,006.
Mulroy has sold 55,467 shares in the prior 12 days (5/15-5/26) for ~$3.33M total.
The proposed sale is via Morgan Stanley Smith Barney, with shares acquired from stock option exercise on 5/27/2026.
No lock-up expiration or earnings catalyst is indicated in the filing; the sales appear discretionary.

Financial Impact

CEO selling ~$585K in proposed sale, with $3.33M in recent prior sales over 12 days; total insider selling of ~$3.9M in under two weeks.

insider selling volumeCEO holdings reduction

Risk Factors

CEO selling may signal lack of confidence in near-term prospects or upcoming negative catalyst.
Continued insider selling could pressure stock price and erode investor sentiment.
No offsetting insider buying or positive corporate events in the filing to counterbalance the selling.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

89% bullish (18 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

Document	Accession Number
144 Filing (Primary)	0001950047-26-005168
Document: 0001950047-26-005168-index.html	0001950047-26-005168
Document: 0001950047-26-005168.txt	0001950047-26-005168

17 reports for ANAB

T+1T+5T+20T+60

86% Hit rate 6 of 7 directional calls best @ T+60▲ +41.26%Mar 3, 2026

Filters

Reports for ANAB — sortable, filterable
	Type				Now
Jun 11, 2026 1d ago	144 BEARISH ★ 6/10	$54.24 awaiting T+1	awaiting T+1	—	$56.07 (−3.38%)
Jun 10, 2026 2d ago	144 BEARISH ★ 5/10	$51.96 awaiting T+1	awaiting T+1	—	$56.07 (−7.91%)
Jun 8, 2026 4d ago	144 BEARISH ★ 5/10	$51.38 awaiting T+1	awaiting T+1	—	$56.07 (−9.14%)
Jun 5, 2026 7d ago	144 BEARISH ★ 5/10	$50.58 awaiting T+1	awaiting T+1	—	$56.07 (−10.85%)
Jun 5, 2026 7d ago	144 BEARISH ★ 5/10	$51.33 awaiting T+1	awaiting T+1	—	$56.07 (−9.23%)
Jun 3, 2026 9d ago	144 BEARISH ★ 5/10	$51.67 $50.37	▲ +2.52%	▼ −0.08%	$56.07 (−8.52%)
Jun 1, 2026 11d ago	144 BEARISH ★ 5/10	$51.26 $51.24	▲ +0.04%	▼ −0.68%	$56.07 (−9.38%)
May 29, 2026 14d ago	8-K NEUTRAL ★ 2/10	$53.14 $51.26	▼ −3.54%	▼ −3.69%	$56.07 (+5.51%)
May 28, 2026 15d ago	144 NEUTRAL ★ 3/10	$55.67 $53.14	▼ −4.54%	▼ −4.80%	$56.07 (+0.72%)
May 27, 2026 16d ago	144 BEARISH ★ 6/10	$57.02 $55.67	▲ +2.37%	▲ +2.61%	$56.07 (+1.67%)

US Market Status

Market Closed — Opens Mon (50h 27m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access